U.S. Markets closed

CBD Brands Initiates Study to Investigate a Novel Cannabidiol Lotion for the Treatment of Atopic Dermatitis (Eczema)

The study aims to provide a preliminary assessment of the safety and efficacy of proprietary CBD infused lotion as a treatment for atopic dermatitis (eczema).

JUPITER, Fla., Dec. 2, 2019 /PRNewswire/ -- Today CBD Brands, a cutting-edge wellness brand dedicated to exploring the multiple therapeutic and medical uses of cannabidiol (CBD) via a multitude of convenient products, announced that it has initiated a clinical study to investigate the efficacy and safety of its proprietary CBD infused lotion formulations in the treatment of atopic dermatitis (eczema).

(PRNewsfoto/CBD Brands, Inc.)

The study is a double-blinded placebo controlled study with a total population of 90 subjects to be enrolled. The subjects will be randomly selected to receive one of three formulations including a placebo. This is a multi-center pilot study and subjects will apply the interventional treatment at home. All data collection will be performed at the clinical trial sites.

About CBD Brands, Inc.
CBD Brands is a cutting-edge wellness company developing a proprietary line of products designed to explore the multiple therapeutic and medical uses of cannabidiol (CBD). It is dedicated to advancing research into the medical and therapeutic uses of CBD for treatment and relief of ultraviolet exposure, psoriasis, eczema, skin aging, and other ailments. The company was formed in 2018 and is headquartered in Jupiter, Florida. For investor relations, please visit CBD Brands online, or follow the company on Twitter and LinkedIn.

Safe Harbor Statement
To the extent any statements contained in this presentation of CBD Brands, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company concerning future events and are subject to risks, uncertainties, assumptions and other factors relating to the company's industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/cbd-brands-initiates-study-to-investigate-a-novel-cannabidiol-lotion-for-the-treatment-of-atopic-dermatitis-eczema-300967507.html

SOURCE CBD Brands